Sign in
Taking peoplePhase 3

Once-daily mexiletine versus placebo for myotonic dystrophy type 1 and type 2

Tests mexiletine against placebo in people with myotonic dystrophy type 1 or type 2.

Key facts

Who runs it
Lupin Ltd.
Where
Belgium, Denmark, Germany, Italy, Spain, and United Kingdom7 sites in 6 countriesChoose a country to see its sites
Trial code
Registry title
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Status
Recruiting
Phase
Phase 3
People taking part
176 people, planned
Started
13 Feb 2025
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Mexiletine granules for prolonged-release oral suspension
  • Placebo
Record updated
24 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 16 or older with myotonic dystrophy type 1 or type 2, confirmed by a gene test. They must have grip myotonia, which means slow release of the hand after gripping.

Age
16 years and older
Sex
Male, or female who is not pregnant
Disease stage
DM1 or DM2. Hand grip relaxation is delayed by ≥ 3 seconds after a maximum squeeze. People must be able to walk 10 meters on their own, and a cane, walker or braces are allowed. They need enough finger strength to grip the test handle. DM1 patients need a MIRS muscle score of 2, 3 or 4. BMI must be 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg (99 lb).
Earlier treatment
No mexiletine within 4 weeks before Day 1. No other anti-myotonic treatment within 4 weeks before Day 1 or 5 half-lives, whichever is longer. Examples are propafenone, flecainide, lamotrigine and carbamazepine.
Biomarker or test result
DM1 or DM2 confirmed by a genetic test.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Serious heart problems, such as conduction blocks, rhythm problems, heart failure, a pacemaker or an ICD
  • Severe kidney problems (GFR < 30 mL/min)
  • Using a wheelchair or confined to bed, or more than 5 falls in the past 12 months
  • Allergy to mexiletine or local anesthetics

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • DM1 or DM2 diagnosis confirmed genetically
  • Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age)
  • Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment
  • Male or non-pregnant female ≥16 years of age
  • Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg
  • Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug
  • No significant cardiac abnormalities as determined by a cardiologist's assessment
  • Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia
  • Presence of clinical handgrip myotonia (delayed relaxation of grip of ≥ 3 seconds after maximum voluntary contraction) at screening using VHOT
  • Be able to walk independently 10 meters (cane, walker, orthoses allowed)
  • DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4.-

Who cannot take part

  • Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness
  • Treatment with mexiletine within 4 weeks prior to baseline (Day 1)
  • Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs
  • Use of any concomitant medications that could increase the cardiac risk
  • Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery
  • Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc
  • Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation
  • Known allergy to mexiletine or any local anesthetics
  • Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min)
  • Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) at screening (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator
  • Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment
  • Any cardiac safety associated condition including any of the following criteria detected by screening cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:; PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG; Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block; Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds); Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia; Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves; New York Heart Association (NYHA) Class II to IV heart failure; Left ventricular systolic dysfunction with ejection fraction <50%; Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM)); Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant); Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem); Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded; Presence of symptomatic coronary artery disease
  • Are pregnant or lactating
  • High incidence of falls or fall-associated fractures (>5 falls during the past 12 months)
  • Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer
  • Wheelchair-bound or bed-ridden

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)

Read full original descriptionShow less

Study website: https://myotonicdystrophystudy.com/

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    0 mg (matching sachet volumes to low, medium and high dose active drug)

  • Mexiletine prolonged-release (PR)Existing treatment, for comparison

    Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)

    Treatment: Mexiletine granules for prolonged-release oral suspension

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
Plain-language title
Once-daily mexiletine versus placebo for myotonic dystrophy type 1 and type 2Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
24 September 2026